Literature DB >> 23269975

High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.

Eileen M Bauer1, Richard Shapiro, Han Zheng, Ferhaan Ahmad, David Ishizawar, Suzy A Comhair, Serpil C Erzurum, Timothy R Billiar, Philip M Bauer.   

Abstract

Survival rates for patients with pulmonary hypertension (PH) remain low, and our understanding of the mechanisms involved are incomplete. Here we show in a mouse model of chronic hypoxia (CH)-induced PH that the nuclear protein and damage-associate molecular pattern molecule (DAMP) high mobility group box 1 (HMGB1) contributes to PH via a Toll-like receptor 4 (TLR4)-dependent mechanism. We demonstrate extranuclear HMGB1 in pulmonary vascular lesions and increased serum HMGB1 in patients with idiopathic pulmonary arterial hypertension. The increase in circulating HMGB1 correlated with mean pulmonary artery pressure. In mice, we similarly detected the translocation and release of HMGB1 after exposure to CH. HMGB1-neutralizing antibody attenuated the development of CH-induced PH, as assessed by measurement of right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vascular remodeling and endothelial activation and inflammation. Genetic deletion of the pattern recognition receptor TLR4, but not the receptor for advanced glycation end products, likewise attenuated CH-induced PH. Finally, daily treatment of mice with recombinant human HMGB1 exacerbated CH-induced PH in wild-type (WT) but not Tlr4(-/-) mice. These data demonstrate that HMGB1-mediated activation of TLR4 promotes experimental PH and identify HMGB1 and/or TLR4 as potential therapeutic targets for the treatment of PH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23269975      PMCID: PMC3576475          DOI: 10.2119/molmed.2012.00283

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  55 in total

Review 1.  Development and pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Steven H Abman; Thomas Braun; Frédérique Capron; Troy Stevens; Patricia A Thistlethwaite; Sheila G Haworth
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis.

Authors:  Chhinder P Sodhi; Xia-Hua Shi; Ward M Richardson; Zachary S Grant; Richard A Shapiro; Thomas Prindle; Maria Branca; Anthony Russo; Steven C Gribar; Congrong Ma; David J Hackam
Journal:  Gastroenterology       Date:  2009-09-26       Impact factor: 22.682

3.  TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

Authors:  Deepak Mittal; Fabiana Saccheri; Emilie Vénéreau; Tobias Pusterla; Marco E Bianchi; Maria Rescigno
Journal:  EMBO J       Date:  2010-06-04       Impact factor: 11.598

4.  Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome.

Authors:  G Dupire; C Nicaise; V Gangji; M S Soyfoo
Journal:  Scand J Rheumatol       Date:  2012-01-17       Impact factor: 3.641

Review 5.  The role of HMGB1/RAGE in inflammatory cardiomyopathy.

Authors:  Hans C Volz; Ziya Kaya; Hugo A Katus; Martin Andrassy
Journal:  Semin Thromb Hemost       Date:  2010-04-22       Impact factor: 4.180

Review 6.  The receptor for advanced glycation end products (RAGE) and the lung.

Authors:  Stephen T Buckley; Carsten Ehrhardt
Journal:  J Biomed Biotechnol       Date:  2010-01-19

Review 7.  Inflammation, growth factors, and pulmonary vascular remodeling.

Authors:  Paul M Hassoun; Luc Mouthon; Joan A Barberà; Saadia Eddahibi; Sonia C Flores; Friedrich Grimminger; Peter Lloyd Jones; Michael L Maitland; Evangelos D Michelakis; Nicholas W Morrell; John H Newman; Marlene Rabinovitch; Ralph Schermuly; Kurt R Stenmark; Norbert F Voelkel; Jason X-J Yuan; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

8.  TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells.

Authors:  Rolf Spirig; Inga Potapova; Jane Shaw-Boden; Janice Tsui; Robert Rieben; Sidney G Shaw
Journal:  Mol Immunol       Date:  2009-06-25       Impact factor: 4.407

Review 9.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Alessandra Manes; Luca Negro; Massimiliano Palazzini; Maria Letizia Bacchi-Reggiani; Angelo Branzi
Journal:  Eur Heart J       Date:  2009-01-20       Impact factor: 29.983

10.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice.

Authors:  Laurent Savale; Ly Tu; Dominique Rideau; Mohamed Izziki; Bernard Maitre; Serge Adnot; Saadia Eddahibi
Journal:  Respir Res       Date:  2009-01-27
View more
  43 in total

1.  High-Mobility Group Box 1 From Hypoxic Trophoblasts Promotes Endothelial Microparticle Production and Thrombophilia in Preeclampsia.

Authors:  Yae Hu; Ruhong Yan; Ce Zhang; Zhichao Zhou; Meng Liu; Can Wang; Hong Zhang; Liang Dong; Tiantian Zhou; Yi Wu; Ningzheng Dong; Qingyu Wu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-12       Impact factor: 8.311

2.  Therapeutic Targeting of High-Mobility Group Box-1 in Pulmonary Arterial Hypertension.

Authors:  Neil M Goldenberg; Yijie Hu; Xudong Hu; Allen Volchuk; Yidan D Zhao; Mariya M Kucherenko; Christoph Knosalla; Marc de Perrot; Kevin J Tracey; Yousef Al-Abed; Benjamin E Steinberg; Wolfgang M Kuebler
Journal:  Am J Respir Crit Care Med       Date:  2019-06-15       Impact factor: 21.405

3.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

4.  Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension.

Authors:  Eileen M Bauer; R Savanh Chanthaphavong; Chhinder P Sodhi; David J Hackam; Timothy R Billiar; Philip M Bauer
Journal:  Circ Res       Date:  2014-03-17       Impact factor: 17.367

5.  Aged Human Stored Red Blood Cell Supernatant Inhibits Macrophage Phagocytosis in an HMGB1 Dependent Manner After Trauma in a Murine Model.

Authors:  Kent R Zettel; Mitchell Dyer; Jay S Raval; Xubo Wu; John R Klune; Andres Gutierrez; Darrell J Triulzi; Timothy R Billiar; Matthew D Neal
Journal:  Shock       Date:  2017-02       Impact factor: 3.454

Review 6.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 7.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

Review 8.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis.

Authors:  Anandharajan Rathinasabapathy; Erin Bruce; Andrew Espejo; Alana Horowitz; Dhivya R Sudhan; Anand Nair; Dominic Guzzo; Joseph Francis; Mohan K Raizada; Vinayak Shenoy; Michael J Katovich
Journal:  Br J Pharmacol       Date:  2016-08-26       Impact factor: 8.739

Review 10.  The HMGB1-RAGE Inflammatory Pathway: Implications for Brain Injury-Induced Pulmonary Dysfunction.

Authors:  Daniel J Weber; Yohance M Allette; David S Wilkes; Fletcher A White
Journal:  Antioxid Redox Signal       Date:  2015-05-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.